PYC.ASX: Completion of Entitlement Offer

Completion of Entitlement Offer

Stock	PYC Therapeutics Ltd (PYC.ASX)
Release Time	17 Apr 2025, 8:35 a.m.
Price Sensitive	Yes

This feature provides summaries of price-sensitive announcements for companies followed by users on InvestorPA. The summaries are generated by large language models so please interpret with care.

PYC Therapeutics Completes $146m Entitlement Offer

Key Points

Raised ~$146m through Entitlement Offer
Funds will provide >$200m cash runway for next 24 months
Supports human safety and efficacy read-outs for multiple drug candidates

Full Summary

PYC Therapeutics Limited (ASX:PYC) has announced the completion of its Entitlement Offer, raising approximately $146m. The funds will provide the Company with a cash runway of over $200m for the next 24 months, enabling it to progress human safety and efficacy read-outs for multiple first-in-class drug candidates with disease-modifying potential. PYC Therapeutics is a precision medicine company dedicated to developing RNA therapies to treat genetic diseases with no available treatment options. The Entitlement Offer will support the advancement of the Company's pipeline of precision medicine drug candidates over the next two years.

Guidance

The completion of the Entitlement Offer has provided PYC Therapeutics with a cash runway of over $200m for the next 24 months, funding human safety and efficacy read-outs for multiple first-in-class drug candidates.

Outlook

The funds raised through the Entitlement Offer will enable PYC Therapeutics to advance its pipeline of precision medicine drug candidates with disease-modifying potential over the next 24 months.